GSK's RSV Vaccine Approved for At-Risk Adults 50-59
GSK's RSV Vaccine Receives Additional EU Approval
European stock markets are hovering near six-week highs as investors await the release of NVIDIA's financial report.
European stock market closed at its highest level since mid-July on Wednesday, as investors awaited the heavyweight financial report from Nvidia. The Stoxx Europe 600 Index rose 0.3% in closing. The chemical and insurance sectors outperformed the large cap market, while the mining sector experienced the largest decline. GlaxoSmithKline rose after the Supreme Court of Delaware in the United States decided to review the lower court's ruling on the Zantac litigation, which involves allegations of Zantac, the company's heartburn treatment drug, causing cancer. The European stock market has recovered from its decline since August, as investors bet on the Federal Reserve's readiness to cut interest rates and the economy's ability to avoid a recession. The Stoxx 600 Index is currently
Over the Counter (OTC) Drugs Market Report 2024-2030: Features Strategic Company Profiles of 42 Players Including Bayer, Boehringer Ingelheim, GlaxoSmithKline, J&J, Novartis, Pfizer, Sanofi, Takeda Pharma
Daily short sale tracking: Walgreens Boots Alliance's short volume increased by 6 million, with a short sale ratio of 18%
The Supreme Court of Delaware will review the cancer-causing evidence of glaxosmithkline (GSK.US)'s Zantac.
The Supreme Court of Delaware will review a previous ruling by a lower court that allowed the evidence submitted by the plaintiff to be heard in the upcoming trial.
Analyst Issues Sell Rating for GlaxoSmithKline Amid Legal Challenges and Financial Risks
GSK Committed to Defending Itself, Managing This Litigation
Bepirovirsen Granted SENKU Designation in Japan for Chronic Hepatitis B
GSK's Nucala (Mepolizumab) Approved in Japan for Treatment of Adults With Chronic Rhinosinusitis With Nasal Polyps
GSK Shares Rise as Delaware's Top Court to Review Allowing Expert Testimony in Zantac Trial
Express News | GSK Statement On Zantac (Ranitidine) Litigation; Delaware Supreme Court To Review Superior Court's Daubert Decision
Express News | Correction: GSK FDA Breakthrough Therapy News Was Reported On August 20
Barclays Remains a Hold on GlaxoSmithKline (GSK)
Statement: Zantac (Ranitidine) Litigation – Delaware Supreme Court to Review Superior Court's Daubert Decision
5 Things You Need to Know About COVID, Flu and RSV Vaccines This Fall
Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
BioAge Appoints Former GSK CEO Jean-Pierre Garnier as Chair of Its Board of Directors
GlaxoSmithKline (GSK.US) initiates a Phase 2 single-arm clinical study of Dotatilimab in China.
The official website of the China Drug Clinical Trial Registration and Information Disclosure Platform recently announced that GlaxoSmithKline (GSK) has initiated a phase 2 single-arm clinical study of dostarlimab in China, aiming to conduct the study in untreated dMMR/MSI-H locally advanced rectal cancer patients in China.
Express News | The FDA Has Granted Breakthrough Therapy Designation To GSK's GSK5764227, An Investigational B7-H3-Targeted Antibody-drug Conjugate Being Evaluated For Extensive-stage Small-cell Lung Cancer With Disease Progression On Or After Platinum-based...